The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Results from a three-year follow-up of venetoclax in patients with R/R AL amyloidosis
Rahel Schwotzer, MD, University Hospital Zürich, Zürich, Switzerland, discusses the findings from a three-year follow-up of venetoclax in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Of the nine high-risk patients in the initial cohort, two had a very good partial response (VGPR) and seven had a complete response (CR) to venetoclax. Additionally, all patients were still alive at the three-year follow up, which is very promising. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
